Incyte Corp. (NASDAQ: INCY) announced that results from its phase 3 frontMIND study evaluating tafasitamab in first-line diffuse large B-cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE